The biology and pathology of the familial Parkinson's disease protein LRRK2

Parkinson's disease (PD) is typically a sporadic illness, but the past decade has witnessed the identification of mutations responsible for multiple familial forms of the disease. The proposed functions of some of these genes (e.g., E3 ubiquitin ligase, redox‐dependent chaperone) have led to the hypothesis that dysfunction of protein quality control pathways contributes to PD neurodegeneration. However, the key signaling events that act downstream of misfolded proteins to cause cell death remain poorly defined. The discovery of the familial PD kinase leucine‐rich repeat kinase 2 (LRRK2) holds great promise for the elucidation of signaling events relevant to PD neurodegeneration. This review will summarize current knowledge of the clinical and cell biological features of LRRK2, the most common inherited cause of Parkinsonism. © 2010 Movement Disorder Society

[1]  Hansjürgen Bratzke,et al.  Stages in the development of Parkinson’s disease-related pathology , 2004, Cell and Tissue Research.

[2]  Tatiana Foroud,et al.  Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease , 2005, The Lancet.

[3]  P. V. van Haastert,et al.  Roc, a Ras/GTPase domain in complex proteins. , 2003, Biochimica et biophysica acta.

[4]  T. Katada,et al.  GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. , 2007, Biochemistry.

[5]  L. Neckers,et al.  Disruption of Hsp90 Function Results in Degradation of the Death Domain Kinase, Receptor-interacting Protein (RIP), and Blockage of Tumor Necrosis Factor-induced Nuclear Factor-κB Activation* , 2000, The Journal of Biological Chemistry.

[6]  S J Kish,et al.  Biochemical pathophysiology of Parkinson's disease. , 1987, Advances in neurology.

[7]  R. Marconi,et al.  Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease , 2006, European Journal of Human Genetics.

[8]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[9]  Janel O. Johnson,et al.  Clinical and positron emission tomography of Parkinson's disease caused by LRRK2 , 2005, Annals of neurology.

[10]  Vesna Sossi,et al.  PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. , 2005, Brain : a journal of neurology.

[11]  J. Tschopp,et al.  The RIP kinases: crucial integrators of cellular stress. , 2005, Trends in biochemical sciences.

[12]  M. Farrer,et al.  LRRK2: a common pathway for parkinsonism, pathogenesis and prevention? , 2006, Trends in molecular medicine.

[13]  Timothy Lynch,et al.  Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. , 2005, American journal of human genetics.

[14]  Xin Zhao,et al.  Interaction of DJ-1 with Daxx inhibits apoptosis signal-regulating kinase 1 activity and cell death. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[15]  K. Lim,et al.  Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. , 2007, Human molecular genetics.

[16]  A. Lang,et al.  Parkinson's disease. First of two parts. , 1998, The New England journal of medicine.

[17]  David W. Miller,et al.  Kinase activity is required for the toxic effects of mutant LRRK2/dardarin , 2006, Neurobiology of Disease.

[18]  H. Cai,et al.  The Chaperone Activity of Heat Shock Protein 90 Is Critical for Maintaining the Stability of Leucine-Rich Repeat Kinase 2 , 2008, The Journal of Neuroscience.

[19]  Nicholas W Wood,et al.  A common LRRK2 mutation in idiopathic Parkinson's disease , 2005, The Lancet.

[20]  Houeto Jean-Luc.  [Parkinson's disease]. , 2022, La Revue du praticien.

[21]  K. Marder,et al.  Frequency of LRRK2 mutations in early- and late-onset Parkinson disease , 2006, Neurology.

[22]  Shu G. Chen,et al.  The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. , 2007, Experimental cell research.

[23]  P. Emson,et al.  Localization of Parkinson’s disease-associated LRRK2 in normal and pathological human brain , 2007, Brain Research.

[24]  Vincenzo Bonifati,et al.  A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease , 2005, The Lancet.

[25]  E. Tolosa,et al.  Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study , 2008, The Lancet Neurology.

[26]  M. Cookson,et al.  Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase , 2008, Proceedings of the National Academy of Sciences.

[27]  J. Trojanowski,et al.  Biochemical and pathological characterization of Lrrk2 , 2006, Annals of neurology.

[28]  M. Cookson,et al.  The Parkinson Disease-associated Leucine-rich Repeat Kinase 2 (LRRK2) Is a Dimer That Undergoes Intramolecular Autophosphorylation* , 2008, Journal of Biological Chemistry.

[29]  Christine Klein,et al.  LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. , 2006, The New England journal of medicine.

[30]  F. Martinon,et al.  RIP4 (DIK/PKK), a novel member of the RIP kinase family, activates NF‐κB and is processed during apoptosis , 2002, EMBO reports.

[31]  J. Nutt,et al.  LRRK2 G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. , 2006, American journal of human genetics.

[32]  M. Canesi,et al.  The G6055A (G2019S) mutation in LRRK2 is frequent in both early and late onset Parkinson’s disease and originates from a common ancestor , 2005, Journal of Medical Genetics.

[33]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[34]  C. Ross,et al.  Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[35]  R. Uitti,et al.  German-Canadian family (family A) with parkinsonism, amyotrophy, and dementia - Longitudinal observations. , 1997, Parkinsonism & related disorders.

[36]  C. Ross,et al.  Kinase activity of mutant LRRK2 mediates neuronal toxicity , 2006, Nature Neuroscience.

[37]  B. Oostra,et al.  LRRK2 MUTATION ANALYSIS IN PARKINSON DISEASE FAMILIES WITH EVIDENCE OF LINKAGE TO PARK8 , 2008, Neurology.

[38]  Irene Litvan,et al.  Lrrk2 and Lewy body disease , 2006, Annals of neurology.

[39]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[40]  S. Tsuji,et al.  A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2–q13.1 , 2002, Annals of neurology.

[41]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[42]  T. Foroud,et al.  LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8 , 2007, Neurology.

[43]  P. Pollak,et al.  LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. , 2006, The New England journal of medicine.

[44]  Vincenzo Bonifati,et al.  Parkinson's Disease: The LRRK2-G2019S mutation: opening a novel era in Parkinson's disease genetics , 2006, European Journal of Human Genetics.

[45]  O. Sydow,et al.  LRRK2 expression linked to dopamine‐innervated areas , 2006, Annals of neurology.

[46]  A. Abeliovich,et al.  The Familial Parkinsonism Gene LRRK2 Regulates Neurite Process Morphology , 2006, Neuron.

[47]  A. Singleton,et al.  G2019S dardarin substitution is a common cause of Parkinson's disease in a Portuguese cohort , 2005, Movement disorders : official journal of the Movement Disorder Society.

[48]  Andrew Lees,et al.  Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.

[49]  T. Meitinger,et al.  The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. , 2006, Human molecular genetics.

[50]  D W Dickson,et al.  Autosomal dominant parkinsonism associated with variable synuclein and tau pathology , 2004, Neurology.

[51]  M. Farrer,et al.  Lrrk2 R1441C parkinsonism is clinically similar to sporadic Parkinson diseaseSYMBOL , 2008, Neurology.

[52]  R. Nichols,et al.  LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. , 2007, The Biochemical journal.